Sinobioway Medicine(SZ:002581) Ge Long Hui·2025-11-06 11:13Core Viewpoint - ST Unimed (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval from the Beijing Tongren Hospital for the Phase III pivotal registration clinical trial of its innovative drug, SMR001 eye drops, aimed at treating moderate to severe dry eye syndrome [1] Company Summary - SMR001 eye drops are a key development for the company, representing the first recombinant human nerve growth factor-based eye drop formulation in China [1] - The product utilizes a Chinese hamster ovary (CHO) cell expression system, indicating a sophisticated biopharmaceutical development process [1] - SMR001 is designed to repair damaged corneal nerves and promote epithelial regeneration, positioning it as a novel treatment option for moderate to severe dry eye syndrome [1]